Be the most trusted biotech company

Henlius to Release the Preclinical Profiles of 2 ADC Programs at ESMO Congress 2023


Shanghai, China, September 21st, 2023 – Shanghai Henlius Biotech, Inc. (2696. HK) announced that the latest results of two ADC (Antibody-drug Conjugate) products, HLX42, the novel EGFR-targeting ADC, and HLX43, the PD-L1 targeting ADC, will be published as posters at the 2023 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain from October 20-24.

HLX42, as well as HLX43, is conjugated by a specific antibody with cleavable linker and toxic payload. And the payload can be specifically released in the tumor microenvironment. Henlius actively pursued clinical trial approval for its ADC portfolio. In August 2023, the investigational new drug(IND) applications of HLX42 and HLX43 were accepted for review by the National Medical Products Administration (NMPA) of China.

Details of the results to be presented at 2023 ESMO Congress are as follows:

1. HLX42

Title: Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer

Presentation Number: 683P

Onsite Poster display date: Mon, 23.10.2023


2. HLX43

Title: Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models 

Presentation Number: 693P

Onsite Poster display date: Mon, 23.10.2023